INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 410m ago
HOUSE PTR10m ago
SEC 13F10m ago
ROBINHOOD CHAIN10m ago
SEC FORM 4/Option exerciseVerified data

Xu Cong Claire reported NBP

SVP, Clinical Development · NovaBridge Biosciences · Ordinary Shares

Side
M
Value
—
Shares
9,382
Price
—
Executed
May 30, 2026
Disclosed
Jun 2, 2026
Disclosure timeline3 days from execution to publication · legal deadline 2 business days
May 30 executedJun 2, 2026 disclosed

NBP · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Option exercise — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · 3.3% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · NBP

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    WY
    Woo Ian YingDirector
    NBPNovaBridge Biosciences
    Option exercise
    		M—
    13.3K sh
    		Oct 15, 2026Oct 19, 2026
    traded Oct 15, 2026
    		+4dSEC FORM 4

    Evidence

    21
    WY
    Woo Ian YingDirector
    NBPNovaBridge Biosciences
    Option exercise
    		M—
    5,770 sh
    		Oct 15, 2026Oct 19, 2026
    traded Oct 15, 2026
    		+4dSEC FORM 4

    Evidence

    9
    DA
    Dennis Phillip AndrewChief Medical Officer
    NBPNovaBridge Biosciences
    Option exercise
    		M—
    23.7K sh
    		Sep 17, 2026Sep 21, 2026
    traded Sep 17, 2026
    		+4dSEC FORM 4

    Evidence

    9
    DA
    Dennis Phillip AndrewChief Medical Officer
    NBPNovaBridge Biosciences
    Option exercise
    		M—
    10.3K sh
    		Sep 17, 2026Sep 21, 2026
    traded Sep 17, 2026
    		+4dSEC FORM 4

    Evidence

    22
    DA
    Dennis Phillip AndrewChief Medical Officer
    NBPNovaBridge Biosciences
    Open-market sale
    		SELL$5,828
    8,209 sh
    		Sep 18, 2026Sep 21, 2026
    traded Sep 18, 2026
    		+3dSEC FORM 4

    Evidence

    42
    CW
    Cao Sean WuxiongChief Bus. Development Officer
    NBPNovaBridge Biosciences
    Open-market sale
    		SELL$80K
    108.0K sh
    		Sep 9, 2026Sep 11, 2026
    traded Sep 9, 2026
    		+2dSEC FORM 4

    Evidence

    23
    CW
    Cao Sean WuxiongChief Bus. Development Officer
    NBPNovaBridge Biosciences
    Option exercise
    		M—
    104.2K sh
    		Sep 3, 2026Sep 8, 2026
    traded Sep 3, 2026
    		+5dSEC FORM 4

    Evidence

    27
    CW
    Cao Sean WuxiongChief Bus. Development Officer
    NBPNovaBridge Biosciences
    Option exercise
    		M—
    235.1K sh
    		Sep 3, 2026Sep 8, 2026
    traded Sep 3, 2026
    		+5dSEC FORM 4

    Evidence

    27
    CW
    Cao Sean WuxiongChief Bus. Development Officer
    NBPNovaBridge Biosciences
    Option exercise
    		M—
    45.3K sh
    		Sep 3, 2026Sep 8, 2026
    traded Sep 3, 2026
    		+5dSEC FORM 4

    Evidence

    23
    CW
    Cao Sean WuxiongChief Bus. Development Officer
    NBPNovaBridge Biosciences
    Option exercise
    		M—
    102.2K sh
    		Sep 3, 2026Sep 8, 2026
    traded Sep 3, 2026
    		+5dSEC FORM 4

    Evidence

    9
    XC
    Xu Cong ClaireEVP, Clinical Development
    NBPNovaBridge Biosciences
    Option exercise
    		M—
    4,079 sh
    		Aug 30, 2026Sep 1, 2026
    traded Aug 30, 2026
    		+2dSEC FORM 4

    Evidence

    22
    XC
    Xu Cong ClaireEVP, Clinical Development
    NBPNovaBridge Biosciences
    Open-market sale
    		SELL$2,593
    3,282 sh
    		Aug 31, 2026Sep 1, 2026
    traded Aug 31, 2026
    		+1dSEC FORM 4

    Evidence

    5
    XC
    Xu Cong ClaireEVP, Clinical Development
    NBPNovaBridge Biosciences
    Option exercise
    		M—
    9,382 sh
    		Aug 30, 2026Sep 1, 2026
    traded Aug 30, 2026
    		+2dSEC FORM 4

    Evidence

    21
    LA
    Lenz Robert A.Director
    NBPNovaBridge Biosciences
    Option exercise
    		M—
    7,486 sh
    		Aug 22, 2026Aug 25, 2026
    traded Aug 22, 2026
    		+3dSEC FORM 4

    Evidence

    9
    LA
    Lenz Robert A.Director
    NBPNovaBridge Biosciences
    Option exercise
    		M—
    17.2K sh
    		Aug 22, 2026Aug 25, 2026
    traded Aug 22, 2026
    		+3dSEC FORM 4

    Evidence

    17
    XC
    Xu Cong ClaireSVP, Clinical Development
    NBPNovaBridge Biosciences
    Open-market sale
    		SELL$3,992
    4,485 sh
    		Jul 6, 2026Jul 7, 2026
    traded Jul 6, 2026
    		+1dSEC FORM 4

    Evidence

    5
    XC
    Xu Cong ClaireSVP, Clinical Development
    NBPNovaBridge Biosciences
    Option exercise
    		M—
    5,405 sh
    		Jul 4, 2026Jul 7, 2026
    traded Jul 4, 2026
    		+3dSEC FORM 4

    Evidence

    5
    XC
    Xu Cong ClaireSVP, Clinical Development
    NBPNovaBridge Biosciences
    Option exercise
    		M—
    12.4K sh
    		Jul 4, 2026Jul 7, 2026
    traded Jul 4, 2026
    		+3dSEC FORM 4

    Evidence

    9
    FW
    Fu WeiDirector
    NBPNovaBridge Biosciences
    Grant or award
    		A—
    725.1K sh
    		Jun 29, 2026Jun 30, 2026
    traded Jun 29, 2026
    		+1dSEC FORM 4

    Evidence

    9
    FW
    Fu WeiDirector
    NBPNovaBridge Biosciences
    Grant or award
    		A—
    1.09M sh
    		Jun 29, 2026Jun 30, 2026
    traded Jun 29, 2026
    		+1dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002114309-26-000003
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    May 30, 2026
    Published
    Jun 2, 2026
    Ingested by INSIDER
    Nov 5, 03:55 UTC
    Last re-read
    Nov 5, 03:55 UTC

    Extracted facts

    Filer
    Xu Cong Claire
    Role
    SVP, Clinical Development
    Transaction
    Option exerciseAs filed: “M”
    Asset
    NovaBridge Biosciences
    Ticker
    NBP
    Shares
    9,382
    Execution date (reported)
    May 30, 2026
    Owned after transaction
    293.6K shares
    Days from execution to publication
    3

    What this establishes

    Xu Cong Claire filed this Form 4 reporting a option exercise of NBP on May 30, 2026. It became public on Jun 2, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    SVP, Clinical Development
    Xu Cong Clairecik:0002114309
    Issuer
    NovaBridge Biosciencescik:0001778016

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.